

Food and Drug Administration Rockville MD 20857

I-010697-P-0076-EF

APR 0 4 2008

U.S. Department of the Interior
Fish and Wildlife Service
Aquatic Animal Drug Approval Partnership Program
Attention: David Erdahl, Ph.D.
Branch Chief
4050 Bridger Canyon Road
Bozeman, MT 59715

Re: Request to complete the Effectiveness technical section for AQUAFLOR

Dear Dr. Erdahl:

Based on the information in your submission dated October 4, 2007, and the information contained in investigational new animal drug (INAD) file 010697, the Division of Therapeutic Drugs for Food Animals considers the Effectiveness technical section for AQUAFLOR (florfenicol) Type A medicated article for the control of mortality due to streptococcal septicemia associated with *Streptococcus iniae* in hybrid striped bass (*Morone chrysops* x *M. saxatilis*) when administered at a dose of 10 mg florfenicol/kg of fish/day for 10 consecutive days to be complete.

We will make a final decision on whether we can approve your application after we have reviewed all of the data for all applicable technical sections submitted in support of an Administrative New Animal Drug Application (NADA), NADA, or supplemental NADA, and any other information available to us, as a whole, and determined whether the requirements for approval set forth in the Federal Food, Drug, and Cosmetic Act have been met.

If you submit correspondence relating to this letter, you should reference this letter by date and the principal submission identifier found at the top of this letter. If you have any questions about this letter, please contact me at 240-276-8341 or Dr. Donald Prater, Leader, Aquaculture Drugs Team at 240-276-8343.

Sincerely,

Cindy L. Burnsteel, DVM

Acting Director, Division of Therapeutic

andy & Bunsteel DM

Drugs for Food Animals

Office of New Animal Drug Evaluation

Center for Veterinary Medicine

Enclosure:

Freedom of Information Summary (Effectiveness section)